Top Page
BioVaxys Technology
(OTC:BIOV)
BioVaxys Technology (BIOV) vs. S&P 500 (SPY)
BioVaxys Technology Business Overview & Revenue Model
BioVaxys Technology Financial Statement Overview
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | EBIT |
| -3.30M | -2.40M | -4.08M | -6.42M | -1.09M | EBITDA |
| -3.95M | -7.69M | 0.00 | 0.00 | 0.00 | Net Income Common Stockholders |
| -3.95M | -7.69M | -19.36M | -6.47M | -1.18M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 211.81K | 977.00 | 141.90K | 593.12K | 2.42M | Total Assets |
| 1.30M | 113.48K | 865.56K | 8.50M | 10.46M | Total Debt |
| 68.08K | 0.00 | 0.00 | 0.00 | 0.00 | Net Debt |
| -143.73K | -977.00 | -141.90K | -593.12K | -2.42M | Total Liabilities |
| 3.22M | 3.49M | 1.64M | 326.86K | 900.09K | Stockholders Equity |
| -1.92M | -3.37M | -773.53K | 8.18M | 9.56M |
| Cash Flow | Free Cash Flow | |||
| -2.92M | -1.05M | -1.57M | -5.29M | -1.23M | Operating Cash Flow |
| -1.86M | -1.05M | -1.57M | -5.29M | -1.23M | Investing Cash Flow |
| -1.06M | 0.00 | 0.00 | 0.00 | 61.36K | Financing Cash Flow |
| 3.13M | 917.10K | 1.11M | 3.44M | 3.35M |
BioVaxys Technology Technical Analysis
BioVaxys Technology Peers Comparison
BioVaxys Technology Corporate Events
BioVaxys Technology Corp. and SpayVac for Wildlife, Inc. have expanded their license agreement to include commercial aquaculture, targeting the farm-raised fish market with their no-booster fertility-control vaccines. This expansion presents a significant commercial opportunity, particularly in the global market for farm-raised Atlantic salmon and rainbow trout, offering a scalable and cost-effective solution for reproductive control. SpayVac’s vaccines, which utilize a patented liposome-based delivery platform, have shown efficacy in multiple animal species and are advancing towards regulatory approval for use in feral horses and deer populations. The U.S. Bureau of Land Management is a potential customer for managing feral horse populations, which have significant ecological impacts due to their growing numbers.
Spark’s Take on TSE:BIOV Stock
According to Spark, TipRanks’ AI Analyst, TSE:BIOV is a Underperform.
BioVaxys Technology Corp. faces significant financial challenges with no revenue and negative earnings, heavily impacting its overall score. Technical indicators provide mixed signals, while recent corporate events suggest some improvement in financial management. However, the negative valuation metrics highlight the risks involved in the stock.
To see Spark’s full report on TSE:BIOV stock, click here.
BioVaxys Technology Corp. announced the revocation of a management cease trade order by the British Columbia Securities Commission following the completion of its required financial filings. Additionally, the company has settled a debt of $60,000 by issuing 1,200,000 common shares, which are subject to a four-month statutory hold period. This development marks a positive step in BioVaxys’s operational transparency and financial management, potentially enhancing its credibility and stability in the biopharmaceutical industry.
BioVaxys Technology Corp. has announced a debt settlement agreement with THECCSGROUP, where it will issue 1,200,000 common shares to settle a $60,000 debt. This strategic move aims to preserve the company’s cash for working capital, reflecting a focus on financial stability and operational efficiency. The settlement is pending regulatory approvals and highlights BioVaxys’s commitment to maintaining its market position while managing its financial obligations.
BioVaxys Technology Corp. has announced a bi-weekly update regarding a management cease trade order (MCTO) due to delays in filing its audited annual financial statements. The company is working with its auditor to complete the filings by March 30, 2025, and assures that while the MCTO is in effect, public trading of its shares will continue, although trading by its CEO and CFO is restricted. This situation highlights the company’s commitment to resolving the issue while maintaining transparency with stakeholders.
BioVaxys Technology Corp. has been granted a management cease trade order (MCTO) by the British Columbia Securities Commission due to a delay in filing its audited annual financial statements and related documents. The delay is attributed to the recent acquisition of intellectual property and clinical-stage assets from IMV Inc., which has extended the audit process. While the MCTO restricts trading by the company’s CEO and CFO, the general public can continue trading the company’s shares. The company is committed to complying with alternative information guidelines and expects to complete the required filings by March 30, 2025.
BioVaxys Technology Corp. has announced a debt settlement agreement with consultants by issuing shares to preserve cash for working capital. Additionally, the company extended its private placement closing date and closed its final tranche, raising $100,000, which will also be used for working capital. These moves are aimed at strengthening the company’s financial position, potentially impacting its ability to continue developing its innovative therapies and maintain its industry standing.
BioVaxys Technology Corp. has announced a potential delay in filing its annual financial statements due to the complexities involved in auditing its recent acquisition of intellectual property and assets from IMV Inc. The company is proactively seeking a management cease trade order from the British Columbia Securities Commission to address any filing delays, which would prevent its management from trading shares but not affect other stakeholders. This situation highlights the company’s commitment to transparency and suggests that operational and strategic integrations, like the DPX platform, will continue unhindered by this temporary setback.
BioVaxys Technology Corp. has announced an extension to the closing date of its non-brokered private placement offering, originally set for February 7, 2025, and now extended to February 14, 2025. This extension aims to allow additional investors to engage in the final tranche, with proceeds intended for working capital. The announcement could enhance BioVaxys’ financial flexibility and operational capacity, potentially strengthening its market position and offering stakeholders a more robust platform for future developments.